Specific depletion of myelin-reactive B cells via BCR-targeting

A. V. Stepanov, A. A. Belogurov, P. Kothapalli, O. G. Shamborant, V. D. Knorre, G. B. Telegin, A. A. Ovsepyan, N. A. Ponomarenko, S. M. Deyev, S. V. Kaveri, A. G. Gabibov

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

B cells play a crucial role in the development and pathogenesis of systemic and organ-specific autoimmune diseases. Autoreactive B cells not only produce antibodies, but also secrete pro-inflammatory cytokines and present specific autoantigens to T cells. The treatment of autoimmune diseases via the elimination of the majority of B cells using the monoclonal anti-CD19/20 antibody (Rituximab) causes systemic side effects and, thus, requires a major revision. Therapeutic intervention directed towards selective elimination of pathogenic autoreactive B cells has the potential to become a universal approach to the treatment of various autoimmune abnormalities. Here, we developed a recombinant immunotoxin based on the immunodominant peptide of the myelin basic protein (MBP), fused to the antibody Fc domain. We showed that the obtained immunotoxin provides selective in vivo elimination of autoreactive B cells in mice with experimental autoimmune encephalomyelitis. The proposed conception may be further used for the development of new therapeutics for a targeted treatment of multiple sclerosis and other autoimmune disorders.

Original languageEnglish
Pages (from-to)74-79
Number of pages6
JournalActa Naturae
Volume7
Issue number2
Publication statusPublished - 2015
Externally publishedYes

Fingerprint

Myelin Sheath
B-Lymphocytes
Cells
Immunotoxins
Autoimmune Diseases
Antibodies
Disease Eradication
Myelin Basic Protein
T-cells
Autoimmune Experimental Encephalomyelitis
Multiple Sclerosis
Cytokines
T-Lymphocytes
Peptides
Therapeutics

Keywords

  • Autoantigens
  • B cells
  • Immunoglobulins
  • Immunotoxins
  • Multiple sclerosis

ASJC Scopus subject areas

  • Biochemistry
  • Biotechnology
  • Molecular Biology
  • Molecular Medicine

Cite this

Stepanov, A. V., Belogurov, A. A., Kothapalli, P., Shamborant, O. G., Knorre, V. D., Telegin, G. B., ... Gabibov, A. G. (2015). Specific depletion of myelin-reactive B cells via BCR-targeting. Acta Naturae, 7(2), 74-79.

Specific depletion of myelin-reactive B cells via BCR-targeting. / Stepanov, A. V.; Belogurov, A. A.; Kothapalli, P.; Shamborant, O. G.; Knorre, V. D.; Telegin, G. B.; Ovsepyan, A. A.; Ponomarenko, N. A.; Deyev, S. M.; Kaveri, S. V.; Gabibov, A. G.

In: Acta Naturae, Vol. 7, No. 2, 2015, p. 74-79.

Research output: Contribution to journalArticle

Stepanov, AV, Belogurov, AA, Kothapalli, P, Shamborant, OG, Knorre, VD, Telegin, GB, Ovsepyan, AA, Ponomarenko, NA, Deyev, SM, Kaveri, SV & Gabibov, AG 2015, 'Specific depletion of myelin-reactive B cells via BCR-targeting', Acta Naturae, vol. 7, no. 2, pp. 74-79.
Stepanov AV, Belogurov AA, Kothapalli P, Shamborant OG, Knorre VD, Telegin GB et al. Specific depletion of myelin-reactive B cells via BCR-targeting. Acta Naturae. 2015;7(2):74-79.
Stepanov, A. V. ; Belogurov, A. A. ; Kothapalli, P. ; Shamborant, O. G. ; Knorre, V. D. ; Telegin, G. B. ; Ovsepyan, A. A. ; Ponomarenko, N. A. ; Deyev, S. M. ; Kaveri, S. V. ; Gabibov, A. G. / Specific depletion of myelin-reactive B cells via BCR-targeting. In: Acta Naturae. 2015 ; Vol. 7, No. 2. pp. 74-79.
@article{aa3e3ab33db7424d9a32e4e80a80c0ff,
title = "Specific depletion of myelin-reactive B cells via BCR-targeting",
abstract = "B cells play a crucial role in the development and pathogenesis of systemic and organ-specific autoimmune diseases. Autoreactive B cells not only produce antibodies, but also secrete pro-inflammatory cytokines and present specific autoantigens to T cells. The treatment of autoimmune diseases via the elimination of the majority of B cells using the monoclonal anti-CD19/20 antibody (Rituximab) causes systemic side effects and, thus, requires a major revision. Therapeutic intervention directed towards selective elimination of pathogenic autoreactive B cells has the potential to become a universal approach to the treatment of various autoimmune abnormalities. Here, we developed a recombinant immunotoxin based on the immunodominant peptide of the myelin basic protein (MBP), fused to the antibody Fc domain. We showed that the obtained immunotoxin provides selective in vivo elimination of autoreactive B cells in mice with experimental autoimmune encephalomyelitis. The proposed conception may be further used for the development of new therapeutics for a targeted treatment of multiple sclerosis and other autoimmune disorders.",
keywords = "Autoantigens, B cells, Immunoglobulins, Immunotoxins, Multiple sclerosis",
author = "Stepanov, {A. V.} and Belogurov, {A. A.} and P. Kothapalli and Shamborant, {O. G.} and Knorre, {V. D.} and Telegin, {G. B.} and Ovsepyan, {A. A.} and Ponomarenko, {N. A.} and Deyev, {S. M.} and Kaveri, {S. V.} and Gabibov, {A. G.}",
year = "2015",
language = "English",
volume = "7",
pages = "74--79",
journal = "Acta Naturae",
issn = "2075-8251",
publisher = "Park Media Ltd.",
number = "2",

}

TY - JOUR

T1 - Specific depletion of myelin-reactive B cells via BCR-targeting

AU - Stepanov, A. V.

AU - Belogurov, A. A.

AU - Kothapalli, P.

AU - Shamborant, O. G.

AU - Knorre, V. D.

AU - Telegin, G. B.

AU - Ovsepyan, A. A.

AU - Ponomarenko, N. A.

AU - Deyev, S. M.

AU - Kaveri, S. V.

AU - Gabibov, A. G.

PY - 2015

Y1 - 2015

N2 - B cells play a crucial role in the development and pathogenesis of systemic and organ-specific autoimmune diseases. Autoreactive B cells not only produce antibodies, but also secrete pro-inflammatory cytokines and present specific autoantigens to T cells. The treatment of autoimmune diseases via the elimination of the majority of B cells using the monoclonal anti-CD19/20 antibody (Rituximab) causes systemic side effects and, thus, requires a major revision. Therapeutic intervention directed towards selective elimination of pathogenic autoreactive B cells has the potential to become a universal approach to the treatment of various autoimmune abnormalities. Here, we developed a recombinant immunotoxin based on the immunodominant peptide of the myelin basic protein (MBP), fused to the antibody Fc domain. We showed that the obtained immunotoxin provides selective in vivo elimination of autoreactive B cells in mice with experimental autoimmune encephalomyelitis. The proposed conception may be further used for the development of new therapeutics for a targeted treatment of multiple sclerosis and other autoimmune disorders.

AB - B cells play a crucial role in the development and pathogenesis of systemic and organ-specific autoimmune diseases. Autoreactive B cells not only produce antibodies, but also secrete pro-inflammatory cytokines and present specific autoantigens to T cells. The treatment of autoimmune diseases via the elimination of the majority of B cells using the monoclonal anti-CD19/20 antibody (Rituximab) causes systemic side effects and, thus, requires a major revision. Therapeutic intervention directed towards selective elimination of pathogenic autoreactive B cells has the potential to become a universal approach to the treatment of various autoimmune abnormalities. Here, we developed a recombinant immunotoxin based on the immunodominant peptide of the myelin basic protein (MBP), fused to the antibody Fc domain. We showed that the obtained immunotoxin provides selective in vivo elimination of autoreactive B cells in mice with experimental autoimmune encephalomyelitis. The proposed conception may be further used for the development of new therapeutics for a targeted treatment of multiple sclerosis and other autoimmune disorders.

KW - Autoantigens

KW - B cells

KW - Immunoglobulins

KW - Immunotoxins

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84930832039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930832039&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84930832039

VL - 7

SP - 74

EP - 79

JO - Acta Naturae

JF - Acta Naturae

SN - 2075-8251

IS - 2

ER -